Anthelmintic Drugs

Classification (by worm type)

Broad-spectrum: albendazole, mebendazole. Nematode-specific: pyrantel pamoate, ivermectin, DEC(filarial-specific). Cestode-specific: niclosamide, praziquantel. Trematode-specific: praziquantel(also cestodes — broad cross-phylum).

Mechanism

Benzimidazoles(albendazole, mebendazole): bind β-tubulin → inhibit microtubule polymerization → can’t maintain cytoskeleton/transport glucose/divide → energy depletion, death over days. Selectivity = HIGHER affinity for parasitic vs mammalian β-tubulin(real, not absolute) — SAME target as griseofulvin(fungal) + colchicine(mammalian, gout) — one cytoskeletal target, varying selectivity across kingdoms.

Ivermectin: binds glutamate-gated Cl- channels(invertebrate nerve/muscle, NO mammalian counterpart — mammals use GLYCINE-gated at analogous synapses) → sustained Cl- channel opening→hyperpolarization→FLACCID paralysis. TARGET ABSENT in mammals entirely(not just lower affinity) = unusually clean selectivity — SAME “target doesn’t exist in host” logic as echinocandins/β-lactams.

Pyrantel pamoate: depolarizing NMB agent at nematode’s OWN cholinergic NMJ — nicotinic agonist, sustained depolarization→SPASTIC paralysis. OPPOSITE character from ivermectin’s flaccid mechanism — spastic vs flaccid = 2 distinct NM strategies, mirrors depolarizing-vs-non-depolarizing distinction from Skeletal Muscle Relaxants(here on parasite’s NMJ not patient’s).

DEC: mechanism incompletely understood — alters parasite surface membrane→↑susceptibility to HOST immune attack + some direct metabolic disruption. Lymphatic filariasis(W. bancrofti)+loiasis. Caution/staged dosing in HEAVY microfilarial load(Mazzotti reaction risk, below).

Praziquantel: ↑parasite membrane Ca2+ permeability → sustained contraction/spastic paralysis + damages TEGUMENT(outer surface) → exposes to host immune attack(similar spirit to DEC). Broad: trematodes(Schistosoma)+cestodes — unusually wide cross-phylum spectrum.

Niclosamide: inhibits oxidative phosphorylation in cestode mitochondria(uncouples ATP production) → energy depletion, paralyzes SCOLEX(attachment organ) → worm DETACHES+expelled(not necessarily killed outright) — “detach and expel” not “poison to death” logic.

Adverse Effects

Benzimidazoles: well tolerated at SHORT courses(common intestinal nematode Rx). Hepatotoxicity+marrow suppression = concerns at HIGHER/PROLONGED dosing(hydatid disease, neurocysticercosis) — same drug’s risk shifts with INDICATION-SPECIFIC dosing intensity, not fixed. Teratogenic(animal studies) — caution pregnancy, esp 1st trimester.

Ivermectin: well tolerated generally, but specific caution in Loa loa co-endemic areas — heavy Loa loa microfilarial load → severe/fatal ENCEPHALOPATHY post-treatment(rapid microfilarial death in CNS microvasculature) — pretreatment screening consideration in relevant epidemiological context.

DEC: MAZZOTTI REACTION — named severe systemic inflammatory reaction(fever, rash, lymphadenopathy, hypotension) from rapid microfilarial death releasing antigen → hypersensitivity-type response. Mechanistic reason for staged/cautious dosing in heavily-infected patients. Named entity, distinct from generic drug allergy — frequently examined.

Praziquantel: well tolerated; dizziness, GI upset. Neurocysticercosis Rx specifically: similar antigen-release inflammatory concern to Mazzotti(dying CNS cysts→local inflammation/oedema, sometimes +corticosteroids) — SAME “rapid parasite death releases antigen→host inflammatory response” pattern recurring across contexts.

Clinical Relevance

2 recurring themes connect this topic to others: microtubule/tubulin target shared(varying host selectivity) across benzimidazoles+griseofulvin+colchicine; “target absent entirely in host” logic shared by ivermectin’s glutamate-gated channels+echinocandins’ fungal glucan+β-lactams’ bacterial wall. Recognizing SAME underlying principles recurring across drug classes(not fresh-memorized per topic) = efficient way to hold this whole Antimicrobials-adjacent section together.

Classification (by Worm Type Targeted)

Broad-spectrum (effective against multiple nematode types): albendazole, mebendazole
Nematode (roundworm)-specific: pyrantel pamoate, ivermectin, diethylcarbamazine (DEC, specifically for filarial nematodes)
Cestode (tapeworm)-specific: niclosamide, praziquantel
Trematode (fluke)-specific: praziquantel (also active against cestodes, a genuinely broad-spectrum anthelmintic across two different worm phyla)

Mechanism of Action

Benzimidazoles (albendazole, mebendazole): bind β-tubulin in the parasite specifically, inhibiting microtubule polymerization — without functional microtubules, the parasite cannot maintain its cytoskeleton, transport glucose across its own gut lining, or divide, leading to energy depletion and death over days. Selectivity relies on substantially higher binding affinity for parasitic (nematode) β-tubulin than for mammalian β-tubulin — a real but not absolute selectivity margin, worth noting given it is the same fundamental target (tubulin/microtubule function) already seen for entirely different purposes elsewhere (e.g. griseofulvin’s fungal microtubule disruption under Antifungal Drugs, and colchicine’s mammalian-tubulin-targeting anti-gout mechanism) — the same cytoskeletal target, exploited across kingdoms with varying degrees of selectivity depending on how structurally different the target organism’s tubulin is from the human version.

Ivermectin: binds glutamate-gated chloride channels, which are present in invertebrate (nematode and arthropod) nerve and muscle cells but have no counterpart in vertebrate/mammalian tissue (mammals use glycine-gated, not glutamate-gated, chloride channels at the analogous inhibitory synapses) — binding causes sustained chloride channel opening, hyperpolarization, and flaccid paralysis of the parasite’s neuromuscular system. This complete absence of the target in mammals, rather than merely reduced affinity, gives ivermectin an unusually clean selective-toxicity profile (further reinforced by ivermectin’s poor ability to cross the intact mammalian blood-brain barrier even where trace target-like channels might exist centrally) — the same “target simply doesn’t exist in the host” logic already highlighted for echinocandins under Antifungal Drugs and β-lactams under Beta-Lactam Antibiotics, here applied to a neuromuscular rather than cell-wall target.

Pyrantel pamoate: acts as a depolarizing neuromuscular blocking agent at the nematode’s own cholinergic neuromuscular junction — a nicotinic receptor agonist causing sustained depolarization and spastic (not flaccid) paralysis, the mechanistic opposite in character from ivermectin’s flaccid-paralysis mechanism despite both ultimately being neuromuscular-junction-targeting anthelmintics — worth explicitly contrasting spastic-versus-flaccid paralysis as the two distinct neuromuscular strategies this drug class uses, mirroring in spirit the same depolarizing-versus-non-depolarizing distinction already drawn for skeletal muscle relaxants under that topic, though applied here to a parasite’s neuromuscular junction rather than the patient’s own.

Diethylcarbamazine (DEC): mechanism against filarial worms is incompletely understood, but is thought to alter the parasite’s surface membrane in a way that increases its susceptibility to the host’s own immune attack, alongside some direct metabolic disruption — used specifically for lymphatic filariasis (Wuchereria bancrofti) and loiasis, notably requiring caution/staged dosing in patients with heavy microfilarial loads given the risk of a severe inflammatory reaction (below) as large numbers of dying parasites release antigenic material rapidly.

Praziquantel: increases parasite cell membrane permeability to calcium, causing sustained muscular contraction/spastic paralysis (a mechanism distinct from all the above) and damage to the parasite’s tegument (outer surface layer), which — similar in spirit to DEC’s mechanism — exposes the parasite to host immune attack that it would otherwise evade via its normally immune-resistant surface coating. Broad activity across both trematodes (flukes, including Schistosoma) and cestodes (tapeworms), an unusually wide cross-phylum spectrum for a single anthelmintic.

Niclosamide: inhibits oxidative phosphorylation in cestode mitochondria (uncoupling ATP production), causing energy depletion and paralysis of the worm’s scolex (attachment organ) — the worm detaches from the intestinal wall and is expelled, generally without needing to be killed outright, a mechanistically distinct “detach and expel” rather than “poison to death” logic worth noting.

Adverse Effects

Benzimidazoles: generally well tolerated at the short courses used for common intestinal nematode infections; hepatotoxicity and bone marrow suppression are dose/duration-related concerns specifically at the higher, more prolonged doses used for hydatid disease or neurocysticercosis (rather than the single/short-course dosing for simple intestinal worm infections) — a specific, examined point that the same drug’s risk profile shifts meaningfully with indication-specific dosing intensity, not a fixed, dose-independent property. Teratogenic in animal studies — caution in pregnancy, particularly in the first trimester.

Ivermectin: generally well tolerated, but a specific, important caution exists in areas co-endemic for Loa loa (another filarial parasite) — patients with heavy Loa loa microfilarial loads can develop a severe, sometimes fatal encephalopathy after ivermectin treatment (thought related to rapid death of a very large number of microfilariae in the CNS microvasculature), a specific, examined pretreatment screening consideration in relevant geographic/epidemiological contexts.

Diethylcarbamazine: the Mazzotti reaction — a specific, named, severe systemic inflammatory reaction (fever, rash, lymphadenopathy, hypotension) occurring as large numbers of microfilariae die rapidly and release antigenic material, provoking a hypersensitivity-type response — the mechanistic reason for the staged/cautious dosing approach in heavily-infected patients mentioned above, and worth learning as its own named entity given how specifically and frequently it’s examined, distinct from a generic drug allergy.

Praziquantel: generally well tolerated; dizziness, GI upset, and — in patients being treated for neurocysticercosis specifically — a similar antigen-release inflammatory concern to the Mazzotti reaction (dying CNS cysts provoking local inflammation/oedema, sometimes managed with concurrent corticosteroids), the same underlying “rapid parasite death releases antigen, provokes host inflammatory response” pattern recurring across several different antiparasitic contexts in this topic.

Clinical Relevance

Two recurring mechanistic themes connect this topic to others already covered: the microtubule/tubulin target shared (with varying host selectivity) across benzimidazoles, griseofulvin, and colchicine, and the “target absent entirely in the host” logic shared by ivermectin’s glutamate-gated channels, echinocandins’ fungal cell wall glucan, and β-lactams’ bacterial cell wall — recognizing these as the same underlying pharmacological principles recurring across drug classes, rather than memorizing each mechanism freshly per topic, is the efficient way this entire section of Antimicrobials-adjacent pharmacology should be held together.

Spastic (pyrantel, praziquantel) vs flaccid (ivermectin) neuromuscular paralysis mechanisms contrasted at the parasite neuromuscular junction.
Mazzotti reaction mechanism: rapid microfilarial death releasing antigen, provoking host hypersensitivity response.